{"id":406448,"date":"2020-12-30T07:03:34","date_gmt":"2020-12-30T12:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=406448"},"modified":"2020-12-30T07:03:34","modified_gmt":"2020-12-30T12:03:34","slug":"oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/","title":{"rendered":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><br \/>\n        <br \/>\n        <strong>Oxford, UK \u2013 30 December, 2020: <\/strong>Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, notes AstraZeneca PLC (\u201cAstraZeneca\u201d) has announced that their COVID-19 Vaccine, formerly AZD1222, has been authorised for emergency supply in the UK by The UK Medicines and Healthcare products Regulatory Agency (MHRA).<\/p>\n<p align=\"justify\">Key highlights from the announcement were as follows:<\/p>\n<ul type=\"disc\">\n<li>Working with the UK government, first vaccinations to begin early in the New Year<\/li>\n<li>Regulatory interactions continue around the world for next approvals<\/li>\n<li>The authorisation is for immunisation of individuals 18 years or older and recommends two doses administered with an interval of between four and 12 weeks.\u00a0This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.<\/li>\n<\/ul>\n<p align=\"justify\">To view the full announcement from AstraZeneca, please follow this link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sy3fTO9GacrtDCkzTKcMVmGQXS4-KK5aAv9ihWqAPKkO8jgkZy-BheD5bwVFV_Hy3RjTX0ZvPrPeR5vD6Xy8Bm-CSSmLQq4uhLMW6I4YL1WzvM9aZ7yiofFpX-70M6mU1gP_o4E81vBvfl4amyLqhQKMRxCiR1hSPzodumaDIpItkk2U_XFDWwsIqOR0_apk3loe58Z87S5Ilmu4yMbiSg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">(LINK)<\/a><\/p>\n<p align=\"justify\">As announced on 1 September, Oxford Biomedica signed an 18 month supply agreement under a three year Master Supply and Development Agreement with AstraZeneca for large-scale commercial manufacture of their COVID-19 vaccine candidate, AZD1222. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sy3fTO9GacrtDCkzTKcMVvvatjspR_WE2ke0lwa2N2xTQPBLOZvEgPBn5JEC1x8zSGPTh89-1bkbR9CuiF2YbaBPuAlE2eRy0fPIUz6sjGOrFojz1pyqiPro1g7JY9RC2FoyqweXQeu61w0nzoRikSHwiSCcFIJROenbCAJs7XUQJzVWe1udtrYhyCHKAcgHcwmW48ZeDt8QMc5gyEOezg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">(LINK)<\/a><\/p>\n<p align=\"justify\">\n        <strong>John Dawson, Chief Executive Officer of Oxford Biomedica, said:<\/strong><br \/>\n        <em>\u201cThis emergency use authorisation marks a landmark day for the UK in the fight against COVID-19 as the AstraZeneca COVID-19 vaccine can now be delivered to the population, putting us on a path to a more normal way of life. At Oxford Biomedica we are proud to be part of this effort, led by AstraZeneca and Oxford University, to bring a safe and efficacious vaccine to market in less than a year. The team at Oxford Biomedica continues to work tirelessly to maximise production of the vaccine from our commercial manufacturing site, Oxbox, whilst continuing to support all our partners in cell and gene therapy.\u201d<\/em>\n      <\/p>\n<p align=\"center\">\n        <strong>-Ends-<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>\u00a0<\/strong><br \/>\n            <br \/>\n            <strong>Enquiries:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <br \/>\n            <strong>Oxford Biomedica plc <\/strong><\/p>\n<p> John Dawson, Chief Executive Officer<br \/>Stuart Paynter, Chief Financial Officer<br \/>Catherine Isted, Head of Corporate Development &amp; IR<br \/> \u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<br \/> \u00a0<\/p>\n<p> T: +44 (0)1865 783 000<br \/>T: +44 (0)1865 783 000<br \/>T: +44 (0)1865 954 161 \/ E: ir@oxb.com<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>\u00a0<\/strong><br \/>\n            <br \/>\n            <strong>Consilium Strategic Communications<\/strong><\/p>\n<p> Mary-Jane Elliott\/Matthew Neal<\/td>\n<td style=\"vertical-align: top\">\u00a0\u00a0<br \/>\u00a0<\/p>\n<p> T: +44 (0)20 3709 5700<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Oxford Biomedica<\/strong><br \/>\n        <br \/>Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the &#8220;Group&#8221;) have built a sector leading lentiviral vector delivery platform (LentiVector\u00ae), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MiP0MN1OXNBJM_ebprovHACWuV9J0V58a3rrh9MzaQ_UQ49o2dRPB79QhQqO9-aCUu2fJpcxdKfEyTKFZMB2gVA24retLOCFXunLIVYXrnny5sD6wzadIyGS6W35EP0A\" rel=\"nofollow noopener noreferrer\" target=\"_self\"><u>www.oxb.com<\/u><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/982e9867-badf-48c7-8dc3-600fd9df7e0c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oxford, UK \u2013 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, notes AstraZeneca PLC (\u201cAstraZeneca\u201d) has announced that their COVID-19 Vaccine, formerly AZD1222, has been authorised for emergency supply in the UK by The UK Medicines and Healthcare products Regulatory Agency (MHRA). Key highlights from the announcement were as follows: Working with the UK government, first vaccinations to begin early in the New Year Regulatory interactions continue around the world for next approvals The authorisation is for immunisation of individuals 18 years or older and recommends two doses administered with an interval of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-406448","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oxford, UK \u2013 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, notes AstraZeneca PLC (\u201cAstraZeneca\u201d) has announced that their COVID-19 Vaccine, formerly AZD1222, has been authorised for emergency supply in the UK by The UK Medicines and Healthcare products Regulatory Agency (MHRA). Key highlights from the announcement were as follows: Working with the UK government, first vaccinations to begin early in the New Year Regulatory interactions continue around the world for next approvals The authorisation is for immunisation of individuals 18 years or older and recommends two doses administered with an interval of &hellip; Continue reading &quot;Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-30T12:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK\",\"datePublished\":\"2020-12-30T12:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/\"},\"wordCount\":550,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/\",\"name\":\"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\",\"datePublished\":\"2020-12-30T12:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/","og_locale":"en_US","og_type":"article","og_title":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk","og_description":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oxford, UK \u2013 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, notes AstraZeneca PLC (\u201cAstraZeneca\u201d) has announced that their COVID-19 Vaccine, formerly AZD1222, has been authorised for emergency supply in the UK by The UK Medicines and Healthcare products Regulatory Agency (MHRA). Key highlights from the announcement were as follows: Working with the UK government, first vaccinations to begin early in the New Year Regulatory interactions continue around the world for next approvals The authorisation is for immunisation of individuals 18 years or older and recommends two doses administered with an interval of &hellip; Continue reading \"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-30T12:03:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK","datePublished":"2020-12-30T12:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/"},"wordCount":550,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/","name":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky","datePublished":"2020-12-30T12:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0ODMxMCM0MDA4NDUxNzMjNzAwMDEwNTky"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-notes-astrazenecas-covid-19-vaccine-has-been-authorised-for-emergency-supply-in-the-uk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oxford Biomedica notes AstraZeneca\u2019s COVID-19 vaccine has been authorised for emergency supply in the UK"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=406448"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406448\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=406448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=406448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=406448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}